Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab plus ECX vs placebo plus ECX in first-line MET-positive gastric or gastroesophageal junction adenocarcinoma
2011-004923-11Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Rilotumumab + ECX with Placebo + ECX (2 arms). Primary endpoint: Overall survival. Started Nov 2012; status: completed.
02
Drugs
rilotumumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2011-004923-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004923-11.